Cancer is as versatile as humans are; they are very individual and unique. At the moment, there are three possible pharmacological therapy classes to address cancer diseases on a cellular level, including chemotherapy, hormonal therapy, and targeted therapy.
At RGCC Central Europe, we focus on two main goals:
- Advancing the development of innovative anti-cancer drugs that enable targeted cancer therapy, designed to tackle cancer cells with more precision, while minimizing side effects.
- Discovering new biomarkers to enhance cancer diagnosis and prognosis.
To achieve this, we use both reverse and forward pharmacological approaches and combine all necessary areas of bioscience, including cell and molecular biology, protein biochemistry, in addition to bioinformatics and cheminformatics, to investigate certain cancer types.
Clinical relevance is established by comparing our identified targets with transcriptomic profiles of patient-derived cancer cells provided by RGCC Greece, a leading laboratory specialized in liquid biopsy with a primary focus on Circulating Tumor Cells (CTCs). This detailed profiling of the patient-derived samples offers valuable insights into cancer progression and treatment response, supporting the discovery of novel druggable targets for targeted anti-cancer therapy and potential biomarkers for improved cancer diagnostics.
Welmedis GmbH